RODINRescues On reperfusion Damage in cerebral Infarction by Nelonemdaz

• Phase III clinical study in Korea to verify the improvement and neuroprotective effect of nelonemdaz in 496 patients with acute ischemic stroke undergoing surgery to remove a blood clot within 12 hours following last known normal.
• Participating Hospitals (Department of Neurology): 24 University hospitals including Asan Medical Center in Seoul
• IND Approval Date: August 2021 (first patient enrolled on December 25, 2021)
• Clinical trial subject recruitment completed
• Significant results were obtained in the Nelonemdaz-treated group within 60 minutes of arrival at the emergency room.